Commerce Financial institution elevated its place in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.2% within the third quarter, HoldingsChannel experiences. The agency owned 19,413 shares of the corporate’s inventory after buying a further 1,131 shares in the course of the quarter. Commerce Financial institution’s holdings in AstraZeneca have been value $1,512,000 on the finish of the latest reporting interval.
Numerous different giant buyers have additionally just lately purchased and bought shares of the corporate. McClarren Monetary Advisors Inc. boosted its place in shares of AstraZeneca by 320.8% in the course of the third quarter. McClarren Monetary Advisors Inc. now owns 324 shares of the corporate’s inventory value $25,000 after buying a further 247 shares within the final quarter. GHP Funding Advisors Inc. acquired a brand new stake in shares of AstraZeneca within the 2nd quarter valued at $26,000. Capital Efficiency Advisors LLP purchased a brand new place in shares of AstraZeneca within the third quarter valued at $28,000. Pathway Monetary Advisers LLC acquired a brand new place in shares of AstraZeneca in the course of the 1st quarter value $29,000. Lastly, CANADA LIFE ASSURANCE Co lifted its place in shares of AstraZeneca by 40.6% in the course of the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the corporate’s inventory value $34,000 after shopping for a further 146 shares over the past quarter. 20.35% of the inventory is at the moment owned by institutional buyers and hedge funds.
AstraZeneca Inventory Efficiency
Shares of AstraZeneca inventory opened at $65.63 on Friday. The inventory has a market cap of $203.49 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.18 and a beta of 0.47. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month excessive of $87.68. The corporate’s fifty day shifting common is $73.44 and its 200 day shifting common is $77.80. The corporate has a fast ratio of 0.71, a present ratio of 0.93 and a debt-to-equity ratio of 0.71.
AstraZeneca (NASDAQ:AZN – Get Free Report) final launched its quarterly earnings outcomes on Tuesday, November twelfth. The corporate reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The agency had income of $13.57 billion for the quarter, in comparison with analyst estimates of $13.08 billion. AstraZeneca had a return on fairness of 30.01% and a web margin of 12.68%. The enterprise’s income was up 18.0% on a year-over-year foundation. Throughout the identical quarter within the earlier 12 months, the corporate posted $0.87 EPS. Promote-side analysts forecast that AstraZeneca PLC will put up 4.1 EPS for the present 12 months.
Wall Avenue Analyst Weigh In
Numerous analysis companies have issued experiences on AZN. Erste Group Financial institution upgraded AstraZeneca from a “maintain” score to a “purchase” score in a analysis report on Wednesday, September eleventh. UBS Group upgraded shares of AstraZeneca from a “promote” score to a “impartial” score in a analysis report on Wednesday. Deutsche Financial institution Aktiengesellschaft upgraded shares of AstraZeneca from a “promote” score to a “maintain” score in a analysis report on Wednesday, November sixth. Lastly, TD Cowen upped their worth goal on shares of AstraZeneca from $90.00 to $95.00 and gave the inventory a “purchase” score in a report on Monday, August twelfth. Three analysts have rated the inventory with a maintain score, seven have assigned a purchase score and two have assigned a powerful purchase score to the corporate. In response to knowledge from MarketBeat.com, the corporate at the moment has a consensus score of “Average Purchase” and a median goal worth of $89.75.
Learn Our Newest Inventory Report on AZN
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical firm, focuses on the invention, growth, manufacture, and commercialization of prescription medicines. The corporate’s marketed merchandise embrace Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Wish to see what different hedge funds are holding AZN? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Obtain Information & Scores for AstraZeneca Every day – Enter your e-mail deal with under to obtain a concise each day abstract of the newest information and analysts’ rankings for AstraZeneca and associated firms with MarketBeat.com’s FREE each day e-mail e-newsletter.
